This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Husain, S.
Right arrow Articles by Wheat, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Husain, S.
Right arrow Articles by Wheat, L. J.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, December 2008, p. 1760-1763, Vol. 15, No. 12
1071-412X/08/$08.00+0     doi:10.1128/CVI.00226-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Performance Characteristics of the Platelia Aspergillus Enzyme Immunoassay for Detection of Aspergillus Galactomannan Antigen in Bronchoalveolar Lavage Fluid{triangledown}

S. Husain,1 C. J. Clancy,1 M. H. Nguyen,1 S. Swartzentruber,3 H. Leather,2 A. M. LeMonte,3 M. M. Durkin,3 K. S. Knox,4 C. A. Hage,5 C. Bentsen,6 N. Singh,1 J. R. Wingard,2 and L. J. Wheat3*

University of Pittsburgh, Pittsburgh, Pennsylvania,1 University of Florida College of Medicine, Gainesville, Florida,2 MiraVista Diagnostics, Indianapolis, Indiana,3 Southern Arizona VA Health Care System-University of Arizona, Tucson, Arizona,4 Roudebush VA Medical Center-Indiana University School of Medicine, Indianapolis, Indiana,5 Bio-Rad Laboratories, Redmond, Washington6

Received 16 June 2008/ Returned for modification 11 August 2008/ Accepted 2 October 2008

We have evaluated the Platelia Aspergillus enzyme immunoassay for detection of galactomannan in bronchoalveolar lavage (BAL) specimens in solid organ transplant patients with aspergillosis. The precision and reproducibility in serum or BAL to which galactomannan was added were similar. Sensitivity was 81.8% in patients with aspergillosis, and specificity was 95.8% in lung transplant patients who underwent BAL for surveillance for infection or rejection. Among transplant controls, positive results were more common in patients (i) who underwent diagnostic BAL performed for evaluation of symptoms or chest computed tomographic abnormalities, (ii) who had undergone lung transplantation, or (iii) who were colonized with Aspergillus. Galactomannan testing in BAL is useful for diagnosis of aspergillosis in transplant patients. The significance of positive results in patients without confirmed aspergillosis requires further evaluation.

* Corresponding author. Mailing address: MiraVista Diagnostics, 4444 Decatur Blvd., Ste. 300, Indianapolis, IN 46241. Phone: (317) 856-2681. Fax: (317) 856-3685. E-mail: jwheat{at}miravistalabs.com

{triangledown} Published ahead of print on 8 October 2008.

Clinical and Vaccine Immunology, December 2008, p. 1760-1763, Vol. 15, No. 12
1071-412X/08/$08.00+0     doi:10.1128/CVI.00226-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»